← Leaderboards
Edward B Garon
University Of California Los Angeles
$6,470,653
Attributed
$6,667,325
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,667,325 · 4
By mechanism
R01$5,447,781 · 2
K23$826,200 · 1
R21$393,344 · 1
Top collaborators
- Bin Liu2 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Judith Cheryl Gasson$28,230,504
- Antoni Ribas$28,929,216
- Robert M Prins$8,963,397
- Linda M Liau$8,990,878
- Harvey R. Herschman$16,718,124
Others in their field
Top investigators on “Malignant Neoplasm Of Lung”
- David Heimbrook · Leidos Biomedical Research, Inc.$349,639,893
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,674,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,410,512
- Norman Wolmark · Nsabp Foundation, Inc.$54,610,124
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
Research focus
Malignant Neoplasm Of LungCessation Of LifeResponseSpecimenCancer PatientCancer EtiologyUnited StatesEvaluationTumorNon-Small-Cell Lung CarcinomaMutationBiological MarkersClinical DataSamplingEpidermal Growth Factor ReceptorLeadPositioning AttributeClinical TrialsPredictive MarkerBiopsyBak ProteinChemotherapyProgrammed Cell Death Protein 1Gene Expression
Grant awards (17)
HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy$623,527
R01 · FY2025 · CA · contact PI
HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy$225,068
R01 · FY2025 · CA · contact PI
HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy$592,352
R01 · FY2024 · CA · contact PI
HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy$225,068
R01 · FY2024 · CA · contact PI
Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.$209,850
R21 · FY2024 · CA · contact PI
HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy$620,831
R01 · FY2023 · CA · contact PI
Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.$183,494
R21 · FY2023 · CA · contact PI
A model for predicting response to PD-1 inhibitors in NSCLC$635,207
R01 · FY2021 · CA · contact PI
A model for predicting response to PD-1 inhibitors in NSCLC$635,187
R01 · FY2020 · CA · contact PI
A model for predicting response to PD-1 inhibitors in NSCLC$616,200
R01 · FY2019 · CA · contact PI
A model for predicting response to PD-1 inhibitors in NSCLC$635,258
R01 · FY2018 · CA · contact PI
A model for predicting response to PD-1 inhibitors in NSCLC$639,083
R01 · FY2017 · CA · contact PI
Inhibiting EGFR and ER pathways in NSCLC$165,240
K23 · FY2015 · CA · contact PI
Inhibiting EGFR and ER pathways in NSCLC$165,240
K23 · FY2014 · CA · contact PI
Inhibiting EGFR and ER pathways in NSCLC$165,240
K23 · FY2013 · CA · contact PI
Inhibiting EGFR and ER pathways in NSCLC$165,240
K23 · FY2012 · CA · contact PI
Inhibiting EGFR and ER pathways in NSCLC$165,240
K23 · FY2011 · CA · contact PI